Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
erythroid cells
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "erythroid cells" in MCE Product Catalog:
12
12 Publications Verification
UNC0638, a chemical probe, selectively inhibits G9a and GLP histone methyltransferases with IC50 of 15 nM and 19 nM, respectively. UNC0638 inhibits TNBC cell invasion and migration in vitro. UNC0638 is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .
9
9 Cited Publications
Research Areas:
SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
1
1 Cited Publications
Research Areas:
ACA-28 is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth and induces apoptosis. ACA-28 can activate nuclear factor erythroid 2-related factor 2 (Nrf2) signaling via inducing ROS production. ACA-28 can be used for the research of cancer, such as melanoma
.
Cat. No.: HY-159520
CAS No.: 2731294-23-6
Synonyms: Ofirnoflast; HT-6184
Research Areas:
Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .
Target:
Research Areas:
BD-9136 is a selective BRD4 PROTAC degrader with a DC50 of 1.2 nM, and exhibits a selectivity of ≥1000-fold over BRD2 and BRD3. BD-9136 preferentially forms a ternary complex with the BD1 domain of BRD4, and downregulates the expression of B7-H4 by disrupting the PR-P300-BRD4 axis. BD-9136 depletes BRD4 protein in tumor tissues, inhibits tumor growth, reduces B7-H4 protein expression, increases CD8+ T cell infiltration, and enhances tumor sensitivity to anti-PD-L1. Degradation of BRD4 by BD-9136 rescues the erythroid differentiation block induced by LSD1 inhibition, and transient administration restores erythroid output while retaining HbF induction. BD-9136 causes no adverse effects in mice at effective doses. BD-9136 can be used in studies related to acute myeloid leukemia, acute lymphoblastic leukemia and breast cancer .
Cat. No.: HY-W583212
CAS No.: 14354-67-7
Synonyms: ZnMP
Cat. No.: HY-P990129
Target:
Research Areas:
Synonyms: GSK3482364
Target:
Research Areas:
(Rac)-GSK-3484862 (GSK3482364) is a selective, orally active, reversible DNA methyltransferase 1 (DNMT1) inhibitor with an IC50 of 0.4 μM. (Rac)-GSK-3484862 inhibits the methyltransferase activity of DNMT1 independently of DNA incorporation, reduces global DNA methylation levels, and relieves the transcriptional repression of HBG1 and HBG2 genes. (Rac)-GSK-3484862 increases fetal hemoglobin levels and the proportion of red blood cells expressing fetal hemoglobin in erythroid progenitor cells and a transgenic mouse model of sickle cell disease. (Rac)-GSK-3484862 can be used in studies related to sickle cell disease .
Target:
Research Areas:
Oxyphenonium bromide is an orally effective competitive muscarinic acetylcholine receptor (mAChR) antagonist. Oxyphenonium bromide competitively binds to and blocks mAChR, thereby inhibiting the parasympathetic pathway. By inhibiting CHRM4, Oxyphenonium bromide increases cAMP levels and activates the CREB transcriptional program, thereby promoting erythroid progenitor cell expansion. Oxyphenonium bromide can be used in research on asthma, anemia, and gastric ulcers .
Cat. No.: HY-10966R
CAS No.: 405554-55-4
Target:
Research Areas:
SB-590885 (Standard) is the analytical standard of SB-590885 (HY-10966). This product is intended for research and analytical applications. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
Cat. No.: HY-110093
CAS No.: 1255517-77-1
UNC0638 hydrate selectively inhibits G9a and GLP histone methyltransferases with IC50 of 15 nM and 19 nM, respectively. UNC0638 hydrate inhibits TNBC cell invasion and migration in vitro. UNC0638 hydrate is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 hydrate has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .
Cat. No.: HY-B1719AR
CAS No.: 50-10-2
Target:
Research Areas:
Oxyphenonium bromide Standard is the analytical standard of Oxyphenonium bromide (HY-B1719A). This product is intended for research and analytical applications. Oxyphenonium bromide is an orally effective competitive muscarinic acetylcholine receptor (mAChR) antagonist. Oxyphenonium bromide competitively binds to and blocks mAChR, thereby inhibiting the parasympathetic pathway. By inhibiting CHRM4, Oxyphenonium bromide increases cAMP levels and activates the CREB transcriptional program, thereby promoting erythroid progenitor cell expansion. Oxyphenonium bromide can be used in research on asthma, anemia, and gastric ulcers .
Cat. No.: HY-108864
CAS No.: 113427-24-0
Synonyms: Epogen
Target:
Research Areas:
Cat. No.: HY-10966G
CAS No.: 405554-55-4
Cat. No.: HY-P991881
Target:
Research Areas:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
